Infection control is a complex task that spans people, products, and practices in diverse settings. For years, the Healthcare Infection Control Practices Advisory Committee (HICPAC) has provided advice and guidance to the Centers for Disease Control and Prevention (CDC) on how best to prevent infections. These recommendations have focused largely on health care delivery practices and occasionally on general categories of products. With an influx of novel infection control products and growing use of these products by frontline clinicians, an efficient process for developing transparent, rigorous product recommendations that includes myriad data sources was necessary. To address this gap, the CDC asked HICPAC to develop a process that would help inform committees considering product-related recommendations. This article describes the process to develop this approach and provides an outline of how the tool may be used when products with infection control claims are recommended in guidelines or recommendations for infection prevention. 
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T he Healthcare Infection Control Practices Advisory Committee (HICPAC) is a federal advisory committee chartered to provide advice and guidance to the U.S. Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC).
The committee focuses on infection control issues and strategies for surveillance, prevention, and control of health care-associated infections, antimicrobial resistance, and related events in U.S. health care settings (1) .
The CDC has been developing guidelines and recommendations to prevent and control health careassociated infections since the 1970s and with advice from HICPAC since the 1990s. These recommendations have focused on health care delivery practices and occasionally on general categories of products (2, 3) . However, innovations in infection prevention have fueled an influx of novel products into the health care market, with forecasts suggesting a 4.9% annual growth to more than $27 billion in 2020 (4). As a result, a process that is efficient, transparent, and rigorous for determining whether certain products warrant inclusion in CDC and HICPAC prevention recommendations was needed.
To address this gap, the CDC asked HICPAC to develop a workflow for guideline-writing committees considering product-related recommendations. In response, HICPAC convened a "Products and Practices Workgroup" in July 2017 that was charged with developing a process for formulating product recommendations, describing how criteria for recommending products differ from those used for practice-specific recommendations, and providing a rationale for the criteria and for any departures from the processes applied to practice recommendations. It sought to develop a standardized approach for evaluating a product or product class that would help guidelinewriting groups determine whether a product should be included in prevention recommendations. The workflow was not intended to replace existing processes within guidelines, such as those for appraising the quality of peer-reviewed evidence or developing and making recommendations. Rather, its explicit purpose was to augment product evaluation by bringing diverse types of product-relevant data to committees. Recognizing that evaluation of such data would require expertise not always readily available on committees, other subject matter experts, including representatives from professional organizations, the U.S. Food and Drug Administration (FDA), and the CDC, were added to the workgroup.
The Products and Practices Workgroup convened quarterly from July 2017 to November 2018. It provided updates and obtained HICPAC input at the July 2017, November 2017, and May 2018 public meetings held at the CDC in Atlanta, Georgia. It voted to finalize the tool at the November 2018 meeting (5) . This article summarizes the tool and its development process.
SCOPE AND CORE TENETS
The tool is intended to be used by HICPAC and its workgroups when developing guidelines or recommendations for products marketed with infection prevention claims. Its goal is to determine whether a product warrants inclusion or recommendation in a guideline by gathering several sources of data and evidence.
In creating this tool, the workgroup adopted and agreed on several core tenets. First, it committed to developing a process to assess the evidence for products as fairly and completely as possible. Second, the workgroup emphasized that the process should be transparent and reproducible. In this sense, the committee recognized that product innovations may sometimes represent the most effective intervention available to prevent infection. Third, the workgroup emphasized that research used in product reviews and the sources of funding should be evaluated consistently and thoroughly for sources of potential bias. Finally, the workgroup, HICPAC, and CDC leadership recognized that manufacturers do not require a CDC or HICPAC recommendation to implement a product in a health care system; rather, they need evidence that the product works, an implementation opportunity or niche, and a solid economic rationale. However, the workgroup was aware that clinicians often rely on CDC guidelines to support adoption and implementation of products in the health care environment. Therefore, this document was written with end users in mind, and care was taken to ensure rigor at each stage. With these core tenets, the workgroup constructed a process by which evidence for infection prevention products could be assessed by the CDC and HICPAC during guideline development.
METHODS
The workgroup used best practices for consensus decision making when developing the tool (6) . The CDC helped convene meetings and worked closely with HICPAC cochairs to ensure progress. The workgroup began by reviewing existing CDC health care infection control guideline methods and their process for recommendation development (www.cdc.gov/infectioncontrol /guidelines/index.html). Using a collaborative approach, the workgroup discussed how best to tailor the evaluation of evidence to assess products. One of the first challenges was to define which products would be reviewed. Specifically, it recognized the need to consider whether a product is FDA-approved, FDA-cleared, or U.S. Environmental Protection Agency-registered; its availability in the United States; and whether its FDA-approved label contains infection prevention claims. Because infection control products may be used off label in the absence of safety concerns (for example, use of chlorhexidine gluconate in neonates) (7), HICPAC recognized that certain products should not be excluded from review in the absence of a specific label claim. As discussions evolved, it also became apparent that the tool should accommodate evidence beyond peer-reviewed data, such as findings from the FDA approval or premarket clearance processes. Finally, HICPAC determined that human factor aspects, including the workload associated with education, training, and ensuring safe use of the product, should be incorporated into the review process.
Considering these heterogeneous factors, the workgroup outlined a series of steps, or "nodes." These nodes were used to create an algorithmic worksheet to guide product evaluation. Refined drafts of this tool were shared at HICPAC public meetings, and feedback from those sessions was used to iteratively revise the tool.
CRITERIA AND PROCESS FOR PRODUCT REVIEWS
The tool developed by HICPAC is available on the HICPAC Web site (www.cdc.gov/hicpac/workgroup /index.html) and is shown in the Figure ( www.cdc.gov /hicpac/workgroup/product-assessment.html). The tool's algorithm is summarized as follows:
1. Nodes A, B, and C: Initial steps in the workflow focus on establishing whether a product will be reviewed, first by determining whether it is FDAapproved, FDA-cleared, or Environmental Protection Agency-registered with corresponding medical claims. A product that does not have a medical or infection control prevention claim is not eligible for assessment. If a product has appropriate approval, the next steps are to assess whether use in an infection prevention context is on label or off label and, if the latter, to identify any safety concerns for such use. If a product is being used off label and safety concerns exist, HICPAC will not draft recommendations for its use (node C). 2. Nodes D, E, F, and G: These nodes assess the evidence supporting the product's use for infection prevention in the context of approved indications and marketing information. Node D focuses on peer-reviewed data, including metrics for assessing the product's effectiveness and efficacy. Nodes E and F are designed to affirm that the data are linked to the product's indications for use, including marketing information. Node G summarizes the available evidence, including the type and quality, funding sources, and whether the evidence supports current marketing claims. 3. Nodes H and I: After available evidence and marketing claims are assessed, data are synthesized to understand benefits and harms of the product. Incorporating pre-and postmarketing data and available peer-reviewed literature allows for a holistic, transparent, and comprehensive evaluation of all information. Engagement with FDA colleagues to source these data is important. 4. Nodes J, K, L, and M: These nodes focus on assessing the efficacy and effectiveness of the product and include determining whether the evidence supports superiority over the current standard of care, effectiveness of the product as a stand alone intervention, and generalizability across product classes and clinical care settings. Fundamentally, these nodes seek to understand comparability of the product to its predecessors and its potential applicability to varying clinical contexts. 
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Node N: The penultimate step focuses on the resource implications associated with recommending a product for infection prevention. This assessment includes data that summarize human, economic, and social capital related to introducing, implementing, and maintaining a product in a clinical setting, including but not limited to staff education, product care and maintenance, regulatory concerns, and troubleshooting. Therefore, this node includes purchase or acquisition costs of new products or technology as well as ongoing costs that may be incurred from repair, maintenance, and staff training to ensure that the product is being used as intended. The workgroup recognized that these data may frequently be unavailable or missing; however, highlighting such gaps as an opportunity for further product assessment was important. 6. Node O: The final step is a statement summarizing nodes B to M. The statement addresses whether the assessment supports or informs a recommendation for a product in a guideline or related document. If a specific node has no information available or is not relevant, this too is highlighted in the summary statement.
To determine the feasibility of applying the tool, the committee did 3 test runs with products being considered for inclusion in guidelines on infection prevention in neonatal intensive care units (NICUs): silver alginate dressings for the prevention of central line-associated bloodstream infections (CLABSIs), mupirocin ointment for methicillin-resistant Staphylococcus aureus decolonization, and closed medication delivery systems for the NICU CLABSI guideline. Worksheets summarizing the tool's performance during these tests are included in the Supplement (available at Annals.org). The worksheets represent how future products will be evaluated using this tool.
During the test runs, the tool did well both in summarizing available information and in highlighting gaps in the evidence. The time required for product evaluation ranged from 45 to 120 minutes-longer durations were due to challenges in locating source materials required for product review. For example, the workgroup had difficulty locating product labels on the FDA Web site for silver alginate dressings. In addition, understanding breakpoints for harm sometimes proved challenging because silver levels associated with toxicity and degree of systemic absorption were not well reported in neonates, infants, and adults. Similarly, FDA approval for mupirocin for methicillin-resistant S aureus decolonization could not be found. However, because data regarding the efficacy of mupirocin were available in the peer-reviewed literature, the algorithm worked both to summarize data and to isolate key gaps in process measures and knowledge of products.
The tool was extremely useful when assessing the closed medication delivery system for the NICU CLABSI guideline because it led to the discovery that the product was not FDA-approved but rather a homemade, institution-specific device. The algorithm did identify clinically relevant human outcomes and the possibility of increased workload for nurses using the equipment. Evidence on generalizability, effect, and superiority of this product was not available, and the quality of the evidence in the guideline-review process was low. Therefore, the balance of benefits and harms assessed was unclear, and data summated from the tool did not support a recommendation that the product be used in neonates to reduce CLABSI.
DISCUSSION
This article describes the rationale, scope, methods, and construct of a tool that will inform and guide HICPAC and the CDC in reviewing products for infection prevention and control. The stepped algorithm consists of nodes that span labeling, marketing, and regulatory data; evidence supporting use of a product; a summary of benefits and harms; consideration of effectiveness and generalizability; and resource implications. The workflow provides, for the first time, a rigorous, standardized method for reviewing products for infection prevention. It also broadens the type of information guideline writers will be able to review when considering products within infection prevention recommendations.
The HICPAC and CDC approaches to reviewing evidence to inform recommendations for infection prevention practices are well established and incorporate peer-reviewed science and HICPAC expertise. In contrast, no standardized approach to reviewing evidence for infection prevention products existed, in part because the number and types of products available for infection prevention were relatively limited. Advances in technology and the increase in infection prevention products available in the United States bring challenges in performing a thorough and rigorous review. For example, important safety information related to devices may exist in postmarketing databases (8, 9) . In addition, the pace at which new products enter the market exceeds clinician knowledge, awareness, or experience. Because some of the information pertinent to products was not available in peer-reviewed literature, a new approach to reviewing products that is fair and feasible was necessary to address these challenges.
The HICPAC tool will inform infection prevention product recommendations in important ways. First, it can be used to assess the evidence for a novel product or class of products with implications for infection prevention and safety (for example, ultraviolet disinfection lights in guidelines for environmental disinfection). Of note, the tool seeks to gather evidence for a product from several sources (nodes D to N) rather than only from peer-reviewed material. Because the sources of evidence and data quality for devices can vary considerably, the tool casts a broad net for obtaining data to determine whether inclusion in a guideline is warranted. Second, the tool can be used to compare and contrast 2 products in a similar class to determine whether the information available for 1 product might support a stronger, or different, recommendation. Third, this approach gives manufacturers insight into the types of data and evidence that will be used for product assessment. Thus, those interested in ensuring that their products have the best chance to be assessed by HICPAC and its committees may use this tool as a template. Finally, the workflow will help ensure that HICPAC and the CDC make evidence-based, transparent, and rigorous data-driven assessments of the relative merits of products for end users, clinicians, and other key stakeholders. Because the tool includes regulatory aspects related to approvals and product safety, evidence of efficacy and effectiveness, human factorrelated aspects, and costs and resource implications, it is unlike any other checklist or guideline available.
Despite these advantages, the process outlined in this tool also has limitations. First, no specific guidance is provided about which products should be included or processed through this framework when guidelines or recommendations are being written. The CDC and HICPAC update existing recommendations, or develop new recommendations de novo, using a combination of factors that include, but are not limited to, the age of a preexisting recommendation, advances in recently published literature, requests from subject matter experts, and questions asked via CDC information e-mail boxes. When a product is identified as relevant to a guideline update or a guideline-related question, it will be assessed via the algorithm. The purpose of the tool, then, is to apply a standardized process to a product relevant to a guideline-related question, rather than to individually review products themselves. Second, the tool has not been widely applied to many classes of products; consequently, formal validation, including its advantage relative to current approaches and applicability to diverse products, has not been determined. Further, the tool's performance across persons (interrater variation) has yet to be assessed.
Finally, although it is tempting to believe that the process outlined in the algorithm is the approach the CDC will use to make a product recommendation, that is not the intent of the tool. Rather, its purpose is to supplement existing guideline reviews by providing a plurality of data sources to allow for a more thorough and fair product assessment. Finalized worksheets and contents of the evidence search will be made available so that the public can see how the committee reached its conclusions, fostering transparency in the support of any recommendation. Thus, the tool will do more than serve as a fulcrum for the recommendation of a product within a guideline.
Dissemination of the tool and use when reviewing novel and existing products can help improve product assessment, evaluation, and implementation in clinical settings. We believe this approach will help advance the science and safety of products and devices for infection control in U.S. health care settings. 
